UnknownPhase 1NCT02013336
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- South Plains Oncology Consortium
- Principal Investigator
- Paul Harker-Murray, MDMidwest Children's Hospital
- Intervention
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2013 – 2023
Study locations (6)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- UT Southwestern, Dallas, Texas, United States
- MD Anderson Children's Cancer Hospital, Houston, Texas, United States
- Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Midwest Children's Hospital, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02013336 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07054944Tumor-Lymph Node MappingUniversity of Rochester
- RECRUITINGPHASE1, PHASE2NCT06541262Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsMilton S. Hershey Medical Center
- RECRUITINGPHASE1NCT04337177Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid TumorsValent Technologies, LLC